trending Market Intelligence /marketintelligence/en/news-insights/trending/6pvtf10som5ytvtbleplma2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Biocartis, Guangzhou Wondfo Biotech form JV to market cancer platform in China

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Biocartis, Guangzhou Wondfo Biotech form JV to market cancer platform in China

Biocartis Group NV and Guangzhou Wondfo Biotech Co. Ltd. formed an equally owned joint venture to commercialize Idylla in mainland China.

Idylla is a fully automated molecular diagnostics, or MDx, platform used to inform cancer treatment prescriptions.

Biocartis and Guangzhou Wondfo agreed to provide the venture a total of €14 million of equity funding over several tranches.

Biocartis said the Chinese MDx market is expected to reach a total value of $1.5 billion by the end of 2022, driven by rising cancer incidence in the country. The Belgium-based company said Idylla will provide Chinese laboratories and hospitals fast and easy access to diagnostic data.